Myfortic Monotherapy to Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

Trial Profile

Myfortic Monotherapy to Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Mycophenolate sodium (Primary)
  • Indications Islet cell transplant rejection
  • Focus Pharmacodynamics
  • Most Recent Events

    • 12 May 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2020.
    • 12 May 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2020.
    • 16 Dec 2015 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top